Navigating the Biotech Investment Paradox examines how the biotech sector shifted from record investment and resilience during COVID to a more challenging new normal marked by falling valuations and higher performance expectations. While smaller biotech companies gained visibility and funding, many assets stalled in early development and commercial products often underperformed, intensifying pressure to deliver rapid innovation with strong returns. The paper highlights this paradox and outlines a path forward through optimized R&D. Key priorities include integrating systems, improving process efficiency, monetizing data, and maintaining regulatory readiness. It positions modern R&D platforms, such as Dotmatics, as enablers that help biotech companies operate more efficiently, reduce risk,

Join for free to read